Answer:
All alternatives are correct.
Explanation:
During the weight loss process, cellular mitochondria transform the energy reserve arranged as body fat into heat, ATP, water and carbon dioxide. Therefore, none of these forms is "more likely", and fat loss occurs as a result of the release of all these products from cellular metabolism.
Answer:
The answer was A
It's a Heterotroph
It's means they eat thing outside of themselves instead of producing their own food.
I believe it's correct
Explanation:
Answer:
False
Explanation:
The sugars on the basis of the number of glucose or sugar units can be categorized into two categories:
1. Simple sugars: The sugars which contain one or two sugar units called mono and disaccharides.
2. Complex sugars: The sugars which contain more than two sugar units are complex sugars.
The simple sugars like glucose, galactose are easily digested by the digestive system of the human body and easily absorbed by the cells.
Since the simple sugars or simple sugars are small in their structure compared to the complex carbohydrates therefore false is the correct answer.
Answer:
8 miles
Explanation:
Velocity is speed+direction (the speed of something in a given direction). We know that running on a track, one is moving forwards, which is why the velocity given as positive. Now we do some simple algebra. 120 minutes is equal to 2 hours. At a velocity of 4 miles an hour, for 2 hours, you multiply 4x2 and get 8, which is how far (in miles, units are important) the man has traveled once he comes to a stop.
Answer:
Abstract
Down syndrome (DS) is associated with aberrations in genetic, morphological, biochemical and physiological characteristics. A number of genes located on human chromosome 21 (HSA21) encode proteins which are thought to be involved in numerous metabolic pathways, e.g., phosphofructokinase, cystathionine β-synthase etc. Perturbations of the metabolic pathways may lead to altered drug metabolism in DS individuals. We present a review of metabolic aberrations linked to HSA21 genes in DS. We particularly focus on drug disposition, efficacy, sensitivity and toxicity of anti-leukaemic agents including methotrexate, glucocorticoids, anthracyclines and cytarabine in DS leukaemia. The different outcomes of therapy due to differential drug response, varied drug toxicity and treatment related mortality in DS leukaemia is a subject of much research and speculation. Altered drug response in DS individuals may stem from differences in pharmacokinetics, pharmacodynamics and pharmacogenetics. Further large-cohort studies in different age groups dissecting metabolic and molecular pathways involved in drug response may increase our understanding in this regard and stipulate pharmacotherapies in DS.
